Fig. 2

Graphical representation of the economic balance and the relative importance of the savings in indirect costs in comparison with the savings in direct costs derived from the treatment with anti-CGRP MAbs. The main cost of these therapies are in terms of direct expenses (the drugs costs). However, the 93% of the savings are indirect (reduction in absenteeism and presenteeism). This makes the benefit that they socially produce in economic terms not so evident in the first instance in comparison to their costs, but not less important. Image generated using BioRender